(Professor Li Jin, Chief Scientist and President of Shanghai Gaobo Cancer Hospital Affiliated to China Pharmaceutical University)
Shanghai Gaobo Cancer Hospital highly recognizes the future development prospects of IPG7236 and will fully support the clinical research and development work of Immunophage's innovative drug IPG7236 in subsequent cooperation. Currently, driven by technology, policies, and the market, the targeted anti-tumor industry continues to show strong development momentum. This strategic cooperation will fully combine the advantages of Shanghai Gaobo Cancer Hospital in the field of solid tumor disciplines, utilize its powerful clinical medical resources and scientific research platforms, accelerate the transformation process of new targeted anti-tumor drugs from the laboratory to the clinic, and further demonstrate the strong strength of Shanghai Gaobo Cancer Hospital Affiliated to China Pharmaceutical University as a public service platform for clinical research. It will further help the Chinese pharmaceutical industry step onto the world stage and lead a new round of development and transformation in the field of targeted anti-tumor treatment.
Established in 2016, Immunophage Pharmaceuticals is an innovative drug research and development company based on globally leading targets. The company mainly focuses on developing "root-cause" globally innovative drugs (FIC, first in class) for major diseases such as malignant tumors, autoimmune diseases, and neurodegenerative diseases according to their causes. Immunophage Pharmaceuticals is a national high-tech enterprise. It has been rated as a science and technology-based small and medium-sized enterprise in Jiangsu Province, an innovative small and medium-sized enterprise in Jiangsu Province, and has won honors such as an excellent enterprise in the China Innovation and Entrepreneurship Competition, the Golden Horse Award of the China Biopharmaceutical Industry Chain Innovation List, and the title of a potential unicorn enterprise in Jiangsu Province for many times. Immunophage Shanghai R&D Center (Immunophage Shanghai) has also been recognized as a national high-tech enterprise. In the 8 years since its establishment, Immunophage Pharmaceuticals has completed the pre-clinical development of 5 products. The first product, IPG1094, is the world's first small molecule inhibitor of MIF to enter clinical trials and is currently undergoing clinical research for brain metastases of lung cancer; the second product, IPG7236, is the world's first small molecule antagonist of CCR8 to enter clinical trials and is currently in the transition stage from Phase I to Phase II clinical trials, with triple-negative breast cancer as the primary indication; the third product, IPG11406, is the world's first small molecule antagonist of a certain new GPCR to enter clinical trials. It is a drug developed for the root cause of autoimmune diseases and has entered the registration Phase II clinical trial, with lupus nephritis as the primary indication. The fourth product, IPG8294, is the world's first small molecule oral drug targeting NAD+ hydrolase for the treatment of neurodegenerative diseases and mitochondrial diseases to obtain a clinical approval. It received the Orphan Drug designation from the US FDA in August 2024, obtained the FDA clinical approval in October 2024, is applying for the clinical approval from the CDE, and is about to enter clinical trials.
About Immunophage Pharmaceuticals
Established in 2016, Immunophage Pharmaceuticals is an innovative drug research and development company based on globally leading targets. The company mainly focuses on developing "root-cause" globally innovative drugs (FIC, first in class) for major diseases such as malignant tumors, autoimmune diseases, and neurodegenerative diseases according to their causes. Immunophage Pharmaceuticals is a national high-tech enterprise. It has been rated as a science and technology-based small and medium-sized enterprise in Jiangsu Province, an innovative small and medium-sized enterprise in Jiangsu Province, and has won honors such as an excellent enterprise in the China Innovation and Entrepreneurship Competition, the Golden Horse Award of the China Biopharmaceutical Industry Chain Innovation List, and the title of a potential unicorn enterprise in Jiangsu Province for many times. Immunophage Shanghai R&D Center (Immunophage Shanghai) has also been recognized as a national high-tech enterprise. In the 8 years since its establishment, Immunophage Pharmaceuticals has completed the pre-clinical development of 5 products. The first product, IPG1094, is the world's first small molecule inhibitor of MIF to enter clinical trials and is currently undergoing clinical research for brain metastases of lung cancer; the second product, IPG7236, is the world's first small molecule antagonist of CCR8 to enter clinical trials and is currently in the transition stage from Phase I to Phase II clinical trials, with triple-negative breast cancer as the primary indication; the third product, IPG11406, is the world's first small molecule antagonist of a certain new GPCR to enter clinical trials. It is a drug developed for the root cause of autoimmune diseases and has entered the registration Phase II clinical trial, with lupus nephritis as the primary indication. The fourth product, IPG8294, is the world's first small molecule oral drug targeting NAD+ hydrolase for the treatment of neurodegenerative diseases and mitochondrial diseases to obtain a clinical approval. It received the Orphan Drug designation from the US FDA in August 2024, obtained the FDA clinical approval in October 2024, is applying for the clinical approval from the CDE, and is about to enter clinical trials.
About Shanghai Gaobo Cancer Hospital Affiliated to China Pharmaceutical University
Shanghai Gaobo Cancer Hospital Affiliated to China Pharmaceutical University is located in the Waigaoqiao Free Trade Zone in Shanghai and is a private Class III Grade A hospital with key investment from the Waigaoqiao Group. The total construction area of the hospital is 70,000 square meters. The first phase has 406 open beds, and the second phase is under construction and is expected to be put into use in 2026. The first and second phases combined will have about 700 open beds. Adhering to the concept of "Putting Patients' Needs First" of the Gaobo Medical Group, Shanghai Gaobo Cancer Hospital has deeply cultivated the field of solid tumor disciplines, introduced well-known expert teams at home and abroad, and its business scope covers medical services, clinical research, and integrated diagnosis. It is an important part of the Gaobo Innovative Medical Technology Platform. The hospital will be based on public services for clinical research, aim at the diagnosis and treatment of difficult and severe tumors, clinical research, and the industrial transformation of biopharmaceuticals and medical devices, and build a research-oriented hospital that is in line with international standards and meets the innovation needs of China's biopharmaceutical industry. At the same time, Shanghai Gaobo Cancer Hospital has introduced municipal medical insurance, commercial insurance, etc. to improve medical efficiency and optimize the patient experience, providing patients with diversified payment options. As an affiliated unit of China Pharmaceutical University, Shanghai Gaobo Cancer Hospital relies on the advantages of the university in cultivating high-quality talents and conducting cutting-edge scientific research to further promote the development of the research-oriented hospital and strive to solve the practical problem of the low conversion rate of new drug research and development achievements.
About the Waigaoqiao Group
